Published in J Hosp Infect on April 01, 1990
Adenine phosphoribosyltransferase deficiency: 2,8-dihydroxyadenine urolithiasis in a 48-year-old woman. Br J Urol (1988) 1.38
Postoperative urinary retention. I. Incidence and predisposing factors. Scand J Urol Nephrol (1986) 1.29
Acute appendicitis in the aged patient. Study of 300 cases after the age of 60. Arch Surg (1970) 1.27
Alternating mitomycin C and bacillus Calmette-Guerin instillation prophylaxis for recurrent papillary (stages Ta to T1) superficial bladder cancer. Finnbladder Group. J Urol (1996) 1.19
Tumour infiltrating lymphocytes as an independent prognostic factor in transitional cell bladder cancer. Eur J Cancer (1992) 1.18
Strong Stromal Hyaluronan Expression Is Associated with PSA Recurrence in Local Prostate Cancer. Urol Int (2002) 1.12
Screening for carcinoma of the prostate. Rectal examination, and enzymatic and radioimmunologic measurements of serum acid phosphatase compared. Cancer (1985) 1.10
Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer. Br J Cancer (1995) 1.06
Postoperative urinary retention. II. Micturition problems after the first catheterization. Scand J Urol Nephrol (1986) 1.01
Late urodynamic findings after surgery for cauda equina syndrome caused by a prolapsed lumbar intervertebral disk. J Urol (1986) 0.95
Analysis of false-positive BTA STAT test results in patients followed up for bladder cancer. Urology (2001) 0.91
Independent clinical, histological and quantitative prognostic factors in transitional-cell bladder tumours, with special reference to mitotic frequency. Int J Cancer (1992) 0.90
Scandinavian clinical study of finasteride in the treatment of benign prostatic hyperplasia. Eur Urol (1992) 0.89
Serum and tissue tinidazole concentrations after intravenous infusion. Chemotherapy (1983) 0.89
Effect of oral clodronate on bone pain. A controlled study in patients with metastic prostatic cancer. Int Urol Nephrol (1992) 0.88
Gene expression and prostate specificity of human prostatic acid phosphatase (PAP): evaluation by RNA blot analyses. Biochim Biophys Acta (1990) 0.88
Bladder dysfunction and its manifestations following abdominoperineal extirpation of the rectum. Ann Surg (1974) 0.87
Purification of human prostatic acid phosphatase by affinity chromatography and isoelectric focusing. Part I. Clin Chem (1978) 0.87
Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. The Scandinavian BPH Study Group. Urology (1995) 0.87
The simultaneous radioimmunoassay of seven steroids in human spermatic and peripheral venous blood. J Clin Endocrinol Metab (1977) 0.86
Cytostatic effect of different strains of Bacillus Calmette-Guérin on human bladder cancer cells in vitro alone and in combination with mitomycin C and interferon-alpha. Urol Res (1992) 0.86
The prognostic value of inducible nitric oxide synthase in local prostate cancer. BJU Int (2000) 0.85
Serum steroids in normal males and patients with prostatic diseases. Clin Endocrinol (Oxf) (1978) 0.85
User requirements and standards for PACS. 2nd Japan-Nordic PACS Symposium. Comput Methods Programs Biomed (1992) 0.85
Concentrations of metronidazole and tinidazole in abdominal tissues after a single intravenous infusion and repetitive oral administration. Chemotherapy (1984) 0.84
Spontaneous peripelvic extravasation of urine as a cause of acute abdomen. Scand J Urol Nephrol (1993) 0.84
Flow cytometry in comparison with mitotic index in predicting disease outcome in transitional-cell bladder cancer. Int J Cancer (1993) 0.84
Concentrations of metronidazole and tinidazole in male genital tissues. Antimicrob Agents Chemother (1985) 0.83
Effect of estrogen on the serum cholesterol and triglyceride levels of prostatic cancer patients. J Urol (1971) 0.82
Utilization of the intestine in surgery for major urological complications following gynaecological cancer. Ann Chir Gynaecol Fenn (1972) 0.82
Orchiectomy versus oestrogen in the treatment of advanced prostatic cancer. Br J Urol (1991) 0.82
Peripheral and prostatic vein steroid concentrations in benign prostatic hypertrophy patients before and after removal of the adenoma. Scand J Urol Nephrol (1980) 0.81
Intravesical chemotherapy (mitomycin C) versus immunotherapy (bacillus Calmette-Guérin) in superficial bladder cancer. Eur Urol (1991) 0.81
Efficacy and safety of clean intermittent catheterization in adults. Eur Urol (1991) 0.80
Grading of superficial bladder cancer by quantitative mitotic frequency analysis. J Urol (1993) 0.80
Prognostic value of CD44 standard, variant isoforms 3 and 6 and -catenin expression in local prostate cancer treated by radical prostatectomy. Eur Urol (2000) 0.80
Alternating mitomycin C and bacillus Calmette-Guerin instillation therapy for carcinoma in situ of the bladder. The Finnbladder Group. J Urol (1995) 0.80
Instillation of mitomycin C and doxorubicin in the prevention of recurrent superficial (Ta-T1) bladder cancer. Br J Urol (1987) 0.79
Testicular luteinizing hormone receptor content and in vitro stimulation of cyclic adenosine 3',5'-monophosphate and steroid production: a comparison between man and rat. J Clin Endocrinol Metab (1982) 0.79
Two further males with female karyotypes. Humangenetik (1971) 0.79
Tumor markers. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993. Scand J Urol Nephrol Suppl (1994) 0.79
Ultrastructural localization of glycocalyx domains in human kidney podocytes using the lectin-gold technique. Lab Invest (1985) 0.79
Adriamycin instillations as recurrence prophylaxis in superficial urinary bladder cancer. Ann Chir Gynaecol (1984) 0.79
Promoting shorter duration of ventilator treatment decreases the number of painful procedures in preterm infants. Acta Paediatr (2009) 0.78
Effectiveness of radioimmunoassay of human prostate-specific acid phosphatase in the diagnosis and follow-up of therapy in prostatic carcinoma. Cancer Res (1981) 0.78
Comparison of a long-acting LHRH agonist and polyoestradiol phosphate in the treatment of advanced prostatic carcinoma. An open prospective, randomized multicentre study. Scand J Urol Nephrol (1994) 0.78
Clinical prognostic factors in transitional cell cancer of the bladder. Urol Int (1993) 0.78
Effect of oestrogen on liver function of prostatic cancer patients. Br Med J (1969) 0.77
Pico- and femtosecond laser-induced crosslinking of protein microstructures: evaluation of processability and bioactivity. Biofabrication (2011) 0.77
Effects of estrogen treatment on human testicular unconjugated steroid and steroid sulfate production in vivo. J Clin Endocrinol Metab (1981) 0.77
Androgens and prostate-specific acid phosphatase in whole tissue and in separated epithelium from human benign prostatic hypertrophic glands. Prostate (1981) 0.77
Prognostic factors in WHO grade 2 transitional-cell bladder cancer (TCC); a novel two-grade classification system for TCC based on mitotic index. J Cancer Res Clin Oncol (1992) 0.77
Urodynamics in radical retropubic prostatectomy. Scand J Urol Nephrol (1989) 0.77
The absorption of doxorubicin and mitomycin C in perioperative instillation. An experimental and clinical study. Eur Urol (1985) 0.77
Intravesical cytostatics: pH-dependence of antitumour activity. Urol Res (1985) 0.77
Detecting mitomycin C in human plasma during intravesical therapy. Int Urol Nephrol (1985) 0.77
Effect of mitomycin C and doxorubicin instillation on carcinoma in situ of the urinary bladder. A Finnish multicenter study. Eur Urol (1986) 0.76
Optimising mitomycin C activity during intravesical instillation. Urol Res (1983) 0.76
Sarcoidosis of the bladder: a case report and literature review. J Urol (1989) 0.76
Serum FSH, LH and prolactin in normal males and patients with prostatic diseases. Clin Endocrinol (Oxf) (1977) 0.76
Bladder neck incision or transurethral electroresection for the treatment of urinary obstruction caused by a small benign prostate? A randomized urodynamic study. Scand J Urol Nephrol (1986) 0.76
Piperacillin compared with cefuroxime plus metronidazole in diffuse peritonitis. Eur J Surg (1991) 0.75
Mitomycin-C and BCG in intravesical chemotherapy and immunotherapy of superficial bladder cancer. Finnbladder Research Group. Prog Clin Biol Res (1989) 0.75
Clinical follow-up. Prog Clin Biol Res (1986) 0.75
Prognosis of prostatic cancer. Ann Chir Gynaecol Fenn (1972) 0.75
Radiostrontium in the early diagnosis of bone metastases in patients with prostatic carcinoma. Scand J Urol Nephrol (1971) 0.75
Liver damage and estrogen therapy of prostatic cancer. Case report. Scand J Urol Nephrol (1972) 0.75
[Colovesical fistulas]. Duodecim (1986) 0.75
Can fine needle aspiration biopsy detect incidental prostatic carcinoma (T1) prior to TUR? Eur Urol (1992) 0.75
[Are urate calculi always urates?]. Duodecim (1988) 0.75
Prognostic factors in nodular transitional cell bladder tumours. Scand J Urol Nephrol (1993) 0.75
Independent prognostic factors in T2/T3 transitional cell bladder tumours with special reference to histoquantitative methods. Surg Oncol (1992) 0.75
Rupture of the penis. Ann Chir Gynaecol (1979) 0.75
Voiding rate of the bladder during micturition. I. Evaluation of 131 I-hippuran method in normal cases. Ann Chir Gynaecol Fenn (1972) 0.75
[Metronidazole prophylaxis in excision of the appendix]. Duodecim (1982) 0.75
Atonic bladder in lumbar disk herniation. Acta Chir Scand Suppl (1966) 0.75
[Torsion of intra-abdominal seminoma of testis]. Duodecim (1991) 0.75
[Nonparasitic splenic cysts]. Duodecim (1967) 0.75
Effect of dimethyl sulfoxide on the urinary excretion and on the hypothalamic neurosecretory substance of the rat. Z Gesamte Exp Med (1968) 0.75
[Fournier's gangrene--fulminant inflammation of the urogenital tract]. Duodecim (1990) 0.75
Thromboembolism during estrogen therapy of prostatic cancer. Report on two cases. Scand J Urol Nephrol (1971) 0.75
Condyloma acuminatum giganticum: Buschke-Loewenstein tumour. Scand J Urol Nephrol (1970) 0.75
Prediction of superficial bladder cancer by nuclear image analysis. Eur J Cancer (1992) 0.75
Proliferation indices as independent prognostic factors in papillary Ta-T1 transitional cell bladder tumours. Br J Urol (1993) 0.75
Incidence and fate of renal tuberculosis in patients with bone and joint tuberculosis. Ann Chir Gynaecol Fenn (1966) 0.75
Transureteroureterostomy in the treatment of unilateral ureteral strictures. Ann Chir Gynaecol Fenn (1972) 0.75
Tinidazole prophylaxis in appendicectomies. A controlled study of single-dose versus 3-day therapy. Scand J Gastroenterol (1984) 0.75
Voiding rate of the bladder during micturition. II. Evaluation of the 131 I-Hippuran method in lower urinary tract diseases. Ann Chir Gynaecol Fenn (1972) 0.75
Investigations into bladder dysfunction in prolapse of lumbar intervertebral disc. Ann Chir Gynaecol Fenn Suppl (1968) 0.75
Current concepts in the role of intravesical instillations in the therapy and prophylaxis of superficial transitional-cell cancer of the bladder. The Finnbladder Research Group. World J Urol (1997) 0.75
Methodologies for quantifying the results of intravesical chemotherapy of superficial tumors of the bladder. Med Oncol Tumor Pharmacother (1985) 0.75
Renal hypertension caused by fracture of lumbar spine. J Urol (1972) 0.75
Simultaneous uterine phlebography and retrograde pyelography. A method of investigating ureteric dilatation following pregnancy. Br J Radiol (1972) 0.75
X window system based user interface in radiology. Comput Methods Programs Biomed (1994) 0.75
Blind-ending bifid ureter with uretero-ureteral reflux. Report of two cases. Scand J Urol Nephrol (1972) 0.75